siRNA Opening Up CNS Device Opportunities
This article was originally published in Start Up
Executive Summary
The neurodegenerative disease R&D collaboration between RNA interference specialist Alnylam and device maker Medtronic--the first siRNA-oriented convergence opportunity--appears to be inching closer to the clinic. Key to the program's success to date are refinements in the Medtronic catheter and infusion -pump system used to deliver the Alnylam compund, in keeping with Medtronic's strategic goal of better understanding the mechanics of delivering chronic drugs into the brain.
You may also be interested in...
Building Medtronic Neuro by Trial: An Interview with Richard Kuntz, MD
Medtronic is the acknowledged leader in one of the hottest device sectors-neurostimulation-but even this giant struggles with problems of limited market penetration. So Medtronic is bringing a new approach to this area: an aggressive clinical trials strategy to differentiate its products and drive physician adoption. Who better to run the business than a clinical trials expert? Richard Kuntz talks about future neuro opportunities and the current challenges facing device clinical trials.
Neurostimulation Market Expanding
According to Medtech Insight’s recently published report, US Markets for Neurostimulation Products, the frontier for neural stimulation is expanding rapidly, representing a $628 million market in 2006 that is forecast to grow by over 20% each year to produce sales approaching $2 billion in 2012. Topics discussed include implantable pulse generators, device reimbursement, and current and emerging applications for neurostimulation.
Medtronic: Making Convergence Pay
Medtronic has been a pioneer in drug/device convergence: creating products whose therapeutic benefit stems equally from the features of their drug and device components. Convergence represents one of the medical device industry's most promising opportunities. But getting past the cultural differences between medical device and biotech companies can be huge.